Asset Dedication LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Asset Dedication LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.66K	Hold	5	–	–	﹤0.01%	982
2025 Q4	$1.99K	Hold	5	–	–	﹤0.01%	1008
2025 Q3	$2.28K	Buy	+5	New	+$2.04K	﹤0.01%	1008
2023 Q1	–	Sell	-1	Closed	–	–	946
2022 Q4	$0	Buy	+1	New	+$213	﹤0.01%	989
2021 Q4	–	Sell	-16	Closed	-$3K	–	922
2021 Q3	$3K	Buy	+16	New	+$3K	﹤0.01%	853
2018 Q2	–	Sell	-75	Closed	-$9K	–	612
2018 Q1	$9K	Buy	+75	New	+$9.67K	﹤0.01%	382

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Asset Dedication LLC's ALNY Position: Q1 2026 in Review

Asset Dedication LLC held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 5 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Asset Dedication LLC first reported a position in ALNY in Q1 2018 and has held it in 6 quarters since. The position peaked at $9K in Q1 2018. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Asset Dedication LLC held 5 shares of Alnylam Pharmaceuticals worth $1.66K as of Q1 2026.
Asset Dedication LLC left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Asset Dedication LLC's portfolio in Q1 2026, its #982 holding.
Asset Dedication LLC first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 6 quarters since.
Asset Dedication LLC's Alnylam Pharmaceuticals position peaked at $9K in Q1 2018.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Asset Dedication LLC's 13F filing for Q1 2026, filed 29 May 2026.